Magazine Article | March 1, 2017

Pharmaceuticals Escape The Knife As GOP Mulls Medicaid Reform

Source: Life Science Leader

By John McManus, president and founder, The McManus Group

After bracing for the worst, pharmaceutical executives emerged from a White House meeting with newly installed President Donald J. Trump relatively unscathed. But they soon concluded that his ever-roving spotlight would be back on them in a matter of time and it was on them to develop proposals that would reduce the cost of drugs when patients show up at a pharmacy.

Eli Lilly CEO David Ricks later commented that the discussion focused on consumer out-of-pocket costs, and drug companies need to do a better job “getting discounts through to consumers.”